Dentin Hypersensitivity in Orthodontic Patients: Triple-Blinded, Randomized Trial of Three Desensitizing Agents.

Dentin Hypersensitivity: Triple-Blinded, Multicenter Randomized Trial of Three Desensitizing Dentifrices vs Non-Desensitizing Control

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07641322

Enrollment

200

Registered

2026-06-11

Start date

2026-07-15

Completion date

2026-12-15

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin Desensitizing Agents

Brief summary

The effect of desensitizing agents will be studied on dentin hypersensitivity in orthodontic patients.it is a randomized controlled trial. three experimental groups and one placebo group.

Interventions

OTHERTOOTH PASTE(NHA)

TOOTH PASTES CONTAINING NHA.

OTHERTOOTH PASTE (NOVAMIN)

TOOTH PASTE CONTAINING NOVAMIN

OTHERTOOTH PASTE (PROARGIN)

TOOTH PASTE CONTAINING PROARGIN.

OTHERTOOTH PASTE ( NON DESENSITIZING)

TOOTH PASTE A NON-DESENSITIZING CONTROL

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Orthodontic patients aged 18-40 years. * Presence of mild to moderate dentin hypersensitivity (VAS ≥ 4). * Willingness to comply with a 12-week follow-up period. * No active periodontal disease or untreated caries. * Not pregnant or breastfeeding. * No history of allergy to desensitizing agents

Exclusion criteria

* o Patients with systemic conditions affecting oral health (e.g., diabetes, immunocompromised). * Patients using medications that affect tooth sensitivity (e.g., anti-inflammatory drugs).

Design outcomes

Primary

Measure	Time frame	Description
REDUCTION IN DENTIN HYPERSENSITIVITY	8 WEEKS	Change in dentin hypersensitivity scores from baseline to 8 weeks using the Visual Analog Scale (VAS) and Schiff Cold Air Sensitivity Scale.

Contacts

CONTACTFATIMA KHALID, BDS

fatimakhalid9921@gmail.com03128287657

STUDY_CHAIRDr. Zubair Hassan Awaisi, FCPS

PRINCIPAL NID MULTAN

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 12, 2026